Latest news
What to know about We All Belong: 2023 DEI Impact Review
The annual report details how Johnson & Johnson is harnessing the power of diversity, equity and inclusion to provide better care around the world.
Getting in front of cancer
Every year, roughly 2 million people in the U.S. are newly diagnosed with cancer. But a number of scientific breakthroughs—including ones made at Johnson & Johnson—have dramatically changed what kind of prognosis many of these patients will have.
More from Johnson & Johnson
Inside the development of a revolutionary treatment for blood cancers
In 2014, a Johnson & Johnson therapy gained approval for the treatment of a type of B-cell malignancy—increasing survival rates and changing the way scientists approach cancer treatment. These 8 milestone moments tell the transformational story.
4 things to know about Johnson & Johnson’s 2023 Health for Humanity Report
The annual report details the company’s ongoing work in helping to create a healthier world, building a more diverse and inclusive workforce, championing global health equity and more.
“Lung cancer wasn’t even on my radar. Then I was diagnosed.”
The disease is often detected late—which can have fatal consequences. But thanks to innovations in diagnostic tools, there’s a way to catch lung cancer earlier. Here’s how early detection saved one woman’s life.
“I’m a scientist dedicated to bringing eye-health innovations to the world”
Meet Xiao-Yu Song, Global Head of Research & Development for Vision at Johnson & Johnson, who leads a talented team that creates cutting-edge products addressing vision problems through all stages of life.
Meet a nurse who leads clinical trials to find innovative cancer therapies
Melissa Martinez is a clinical scientist within Johnson & Johnson’s Interventional Oncology R&D group. Not only is she helping to develop lifesaving treatments, she’s redefining what it means to pursue a career in nursing.
How robots are helping personalize knee replacement surgery
For Arthritis Awareness Month, learn the latest about this common procedure and how Johnson & Johnson MedTech is innovating to improve patient outcomes.
Press releases
Johnson & Johnson strengthens pipeline to lead in atopic dermatitis with acquisition of Yellow Jersey Therapeutics
NM26 is a Phase 2-ready, first-in-class bispecific antibody targeting two clinically proven pathways in atopic dermatitis (AD) The Company is leveraging a multi-pathway approach to transform treatment in atopic dermatitis and other immune-mediated diseases
Johnson & Johnson Receives Approval from U.S. FDA and European Commission for SIRTURO® (bedaquiline)
Approvals supported by Phase 3 STREAM Stage 2 study results confirming favorable treatment outcomes compared to injectable-containing regimens Approvals of SIRTURO® follow accelerated approval by U.S. FDA in December 2012 and conditional approval by the EMA in March 2014
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement
CARVYKTI ® is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S. FDA for the treatment of patients with multiple myeloma who have had at least one prior line of therapy
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class
First-and-only FcRn blocker to demonstrate superiority in activities of daily living (MG-ADLa) over placebo when added to standard of care over 24 weeks in antibody positive patients: anti-AChR+, anti-MuSK+, anti-LRP4+
CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients
Pending approval, erdafitinib would become the first therapy targeting FGFR3 alterations in patients with metastatic urothelial carcinoma, one of Europe’s most common cancers1 The CHMP’s recommendation is based on results from Cohort 1 of the Phase 3 THOR study, which showed a 36 percent reduction in the risk of death with erdafitinib versus chemotherapy2
Johnson & Johnson spotlights nipocalimab at FMF Congress 2024 – the first and only FcRn blocker to be studied in maternal fetal diseases
The Phase 3 AZALEA and Phase 3 FREESIA clinical studies are enrolling pregnant individuals who are at risk for severe HDFN and FNAIT These rare and potentially life-threatening alloantibody diseases affecting pregnant individuals and their fetus or newborn currently have no approved treatments
